Peter George – Chairman
Peter George joined Ergomed as a non-executive director in May 2014 and has over 20 years’ experience in the pharmaceutical services industry. Peter stepped down as Chief Executive Ofﬁcer of Clinigen Group plc (AIM: CLIN) at the end of 2016. He started Clinigen in 2010 as a global specialty pharmaceuticals and pharmaceutical services business and by 2016 it had a c.£1bn market cap, being one of the most successful recent floats on AIM.
Prior to Clinigen, he was CEO at Penn Pharma, having led a £67m management buy-out in 2007. Before this, Peter was executive Vice President for Wolters Kluwer Health with responsibility for Europe and Asia Paciﬁc regions.
Peter has also held roles as the Chief Operating Ofﬁcer of Unilabs Clinical Trials International Limited, and Head of Clinical Pathology NHS.
Peter is also Chairman of Wichtig International, Mitre Group Limited, XPG Ltd and Marco Polo Events Limited, companies he owns or has significant holdings in.
Dr Miroslav Reljanovic – Founder and Executive Vice-Chairman
Dr Miroslav Reljanovic is a medical doctor and a board-certified neurologist. Whilst practicing as a physician in a large WHO Collaborating Centre in Zagreb, he was the clinical investigator in numerous Phase II and III studies in the field of neurology and a consultant to various pharmaceutical companies. In 1997 Miro founded Ergomed and he introduced the novel Study Site Coordination model as an intrinsic part of the conduct of clinical studies. This model became a landmark of the Ergomed approach to clinical research, which is paramount to provide high quality.
Miro successfully introduced the first European innovative co-development business model and he has completed several partnerships with European and North American listed biopharmaceutical companies. Together with co-founder Elliot Brown, MB, MRCGP, FFPM, a well-known international expert in drug safety, Miro started PrimeVigilance in 2008, which soon became a leading specialist vendor of contracted pharmacovigilance services to the pharmaceutical industry.
Miro led Ergomed through a successful IPO on the AIM market of the London Stock Exchange in July 2014 and the subsequent completion of five acquisitions and a secondary offering.
Miro transitioned to Executive Vice-Chairman in July 2017 following the appointment of Dr Dan Weng as CEO, in order to support the Board in growing and developing Ergomed’s CRO offering and to provide strategic guidance on Ergomed’s co-development business and wholly-owned pipeline.
Dr Dan Weng – Chief Executive Officer
Dr Weng joined Ergomed as CEO in July 2017 after six years at EPS International Holding Co., where he was Chairman, President and CEO. During his tenure, Dan oversaw significant growth, both organically and through M&A in Asia, the US and Europe, with revenues increasing over five-fold. He was also a Board Director of EPS Holdings, Inc., a global CRO listed on the Tokyo Stock Exchange
Prior to this, Dan delivered growth in executive positions at international CROs including MedPace, Icon Clinical Research, PharmaNet and Quintiles, for over 20 years. His background covers multiple therapeutic areas, supporting all stages of development through to approval.
Dan qualified as a medical doctor at Tongji Medical University, China, and holds an MA in Health Planning, Policy and Management from the University of Leeds, UK. He also held research positions at Harvard Medical School – Massachusetts General Hospital and the University of California.
Stephen Stamp – Chief Finance Ofﬁcer
Stephen Stamp brings to Ergomed more than 30 years of experience in corporate finance and general management in both public and private companies in the UK and the USA. Stephen joins Ergomed from US-based AssureRx Health, Inc, a personalised medicine and bio-informatics company where he was CFO. Prior to this he was CFO of EZCORP, Inc. (NASDAQ:EZPW), a consumer financial services company and Chief Operating Officer and CFO at Xanodyne Pharmaceuticals, Inc, a specialty pharmaceutical company.
Before leaving for the US, Stephen was Group Finance Director at Shire Pharmaceuticals (LSE:SHP, NASDAQ:SHPG) where he led the IPO on London Stock Exchange as well as a number of major acquisitions and financings. During his time at the Company, Shire’s market capitalisation increased from GBP20 million to GBP3.1 billion. He was also Group Finance Director at Regus Plc (LSE:RGU) where he successfully listed the Company on London Stock Exchange Main Market and NASDAQ. Earlier in his career, Stephen was an investment banker with Lazard in London, advising mainly public companies on cross-border M&A and corporate finance. Prior to Lazard, he worked for KPMG in London where he qualified as a Chartered Accountant.
Andrew Mackie – Chief Business Officer
Andrew Mackie joined Ergomed as Chief Business Officer in 2015 having worked with the company as a consultant since 2004. He has been instrumental in developing the co-development business and negotiating the partnerships signed to date. Andrew joins from the Business Development group at Eli Lilly. Previously he was Head of Life Sciences at IP Group and Head of Alliance Management at Antisoma. He brings with him over 25 years’ industry experience in pre-clinical research, clinical development and business development.
After ten years in R&D positions at Novartis, Sanofi and MDS, Andrew joined the UK biotech sector in 1996 at Antisoma as Head of Clinical Development. He establish the clinical development department which ran several oncology phase I to phase III programmes and later managed their strategic alliance with F Hoffman-La Roche. The role also included in-licensing new drug leads. At IP Group, he managed several portfolio companies and worked with the University partners to create new businesses.
Andrew holds a BSc in biochemistry from Queen’s University (Canada), an LLB from the University of London and an MBA from the London Business School.
Christopher Collins – Non-Executive Director
Christopher was the CEO and a founding partner of Code Securities, a healthcare focused advisory and broking ﬁrm, which was formed in 2003, acquired by Nomura in 2005 and continued as Nomura Code Securities until late 2013.
Chris was previously head of the Life Sciences Group at WestLBPanmure, having founded that ﬁrm’s activities in the sector in 1993. He has advised companies at all stages of development on transactions including private ﬁnancings, IPOs, secondary offerings and mergers and acquisitions.
Prior to WestLBPanmure, Chris was Managing Director of Corporate Finance at Panmure Gordon, after eight years as a Director of Corporate Finance at Hoare Govett and nine years in Corporate Finance at Charterhouse Japhet. He has an MBA and read biology at Sussex University.